AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03006172
Drug: Inavolisib
RxNorm normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).
Trial: NCT03006172
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.
Trial: NCT03006172
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.
Trial: NCT03006172
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.
Trial: NCT03006172
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.
Trial: NCT03006172
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive trastuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles, until disease progression or unacceptable toxicity.
Trial: NCT03006172
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive pertuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, until disease progression or unacceptable toxicity.
Trial: NCT04645550
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.
Trial: NCT04645550
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.
Trial: NCT04645550
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.
Trial: NCT04645550
Drug: Dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
Trial: NCT01133444
Drug: Finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finasteride tablets 1 mg
Trial: NCT00111774
Drug: ABX-EGF
RxNorm normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00267020
Drug: enzastaurin
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles
Trial: NCT00267020
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles
Trial: NCT04682431
Drug: PY159 Single agent dose level 2
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Trial: NCT04682431
Drug: PY159 Single agent dose level 3
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Trial: NCT00506519
Drug: Antithrombin alfa (INN name)
DrugBank: Antithrombin Alfa (DB11166)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00506519
Drug: Control (Standard treatment)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04682431
Drug: PY159 Single agent dose level 4
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Trial: NCT04682431
Drug: PY159 Single agent dose level 6
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Trial: NCT04682431
Drug: PY159 Single agent dose level 7
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Trial: NCT04682431
Drug: PY159/Pembrolizumab Combination dose level 1
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of PY159 and given in combination with pembrolizumab
Trial: NCT04682431
Drug: PY159/Pembrolizumab Combination dose level 2
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of PY159 and given in combination with pembrolizumab
Trial: NCT04682431
Drug: PY159/Pembrolizumab Combination dose level 3
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of PY159 and given in combination with pembrolizumab
Trial: NCT04682431
Drug: PY159/Pembrolizumab Combination dose level 4
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of PY159 and given in combination with pembrolizumab
Trial: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 1
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Trial: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 2
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Trial: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 3
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Trial: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 4
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Trial: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 5
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Trial: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 6
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Trial: NCT01665573
Drug: PF-04457845
RxNorm normalized name: PF-04457845
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acquisition of conditioning Administration of drug Extinction of conditioning
Trial: NCT00276731
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00276731
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00276731
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00276731
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04071366
Drug: Itacitinib
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.
Trial: NCT04071366
Drug: Immune effector cell therapy
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.
Trial: NCT03150810
Drug: Pamiparib
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by mouth as a capsule twice daily
Trial: NCT03150810
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ at various doses administered by mouth as a capsule once daily.
Trial: NCT02975882
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02975882
Drug: Sirolimus Albumin-bound Nanoparticles
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02975882
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00669136
Drug: AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
Trial: NCT04325984
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To the Dexamethasone group, at the moment of the induction of anaesthesia, dexamethasone 8 mg is administered.
Trial: NCT03844620
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by mouth
Trial: NCT01973842
Drug: 0.1 mg triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02503709
Drug: CDK Inhibitor AT7519
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02503709
Drug: Onalespib
RxNorm normalized name: Onalespib
DrugBank: Onalespib (DB06306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01973842
Drug: 0.2 mg triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01973842
Drug: 0.4 mg triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03373409
Drug: Albuterol DPI 90mcg
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90mcg will be given on one of the 3 treatment days. One inhalation from the DPI will be used.
Trial: NCT03373409
Drug: Albuterol DPI 180mcg
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the DPI will be used to deliver the 180mcg dose
Trial: NCT03373409
Drug: Albuterol HFA MDI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol HFA MDI delivers 90mcg of albuterol with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the MDI will be used to deliver the 180mcg dose
Trial: NCT04040959
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.
Trial: NCT03232905
Drug: PF-06651600
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06651600 will be administered as tablet
Trial: NCT02056574
Drug: NA-1
RxNorm normalized name: Na-1
DrugBank: Nerinetide (DB12595)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01901146
Drug: ABP 980
RxNorm normalized name: ABPC
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
Trial: NCT01901146
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
Trial: NCT01901146
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
Trial: NCT00127569
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01566474
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
Trial: NCT04563507
Drug: Letrozole 2.5Mg Tab
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
Trial: NCT04563507
Drug: Palbociclib 125mg
RxNorm normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
Trial: NCT01706679
Drug: ATX-101 (10 mg/ml)
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03151967
Drug: Lactobacillus crispatus CTV-05
RxNorm normalized name: LACTOBACILLUS CRISPATUS
DrugBank: Lactobacillus crispatus strain CTV-05 (DB19093)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal applicator with medium containing drug
Trial: NCT01706679
Drug: ATX-101 (20 mg/ml)
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01706679
Drug: Moxifloxacin (400 mg)
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00293475
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IA
Trial: NCT00293475
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IA
Trial: NCT04574076
Drug: Turoctocog alfa pegol (N8-GP)
RxNorm normalized name: Turoctocog alfa pegol
DrugBank: Turoctocog alfa pegol (DB14738)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated with commercially available N8-GP for prophylaxis and treatment of bleeding episodes according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available N8-GP has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Trial: NCT00293475
Drug: Sodium Thiosulfate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02010970
Drug: Group 1 Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: itraconazole capsule
Trial: NCT02010970
Drug: Group 2 Diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem ER tablet
Trial: NCT02010970
Drug: Group 3 Midazolam
RxNorm normalized name: midazolam 14.3 MG/ML
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam syrup
Trial: NCT03765918
Drug: Cisplatin 100 mg/m^2
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle
Trial: NCT00546832
Drug: TDS-943 (topical diclofenac sodium 4% spray)
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02737436
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
Trial: NCT00731432
Drug: Transmucosal Herbal Periodontal Patch (THPP)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch applied to oral gingiva
Trial: NCT04516564
Drug: AK119
RxNorm normalized name: AK119
DrugBank: AK119 (DB16423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of AK119 is administered via intravenous infusion to healthy subjects
Trial: NCT00256100
Drug: Fondaparinux Sodium
RxNorm normalized name: Fondaparinux Sodium
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
Trial: NCT01589029
Drug: CANAKINUMAB (ILARIS®)
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous injection every 8 weeks
Trial: NCT01854073
Drug: Hyoscine butyl bromide
RxNorm normalized name: Butyl Alcohol
DrugBank: Butyl alcohol (DB02145)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01140620
Drug: ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
Trial: NCT01140620
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: risperidone (2 mg) capsule. One dosing of 2 mg.
Trial: NCT01140620
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline infusion. Duration approximately 3 hours
Trial: NCT01140620
Drug: placebo risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: placebo capsule to match risperidone 2 mg capsule
Trial: NCT02337426
Drug: Dimethyl Fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02337426
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04439266
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01410435
Drug: Monofer
RxNorm normalized name: Monofer
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion according to current HB level
Trial: NCT00564785
Drug: Synera(TM)
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synera(TM) patch applied 20 minutes prior to epidural
Trial: NCT03166163
Drug: Azadirachta indica
RxNorm normalized name: Azadirachta indica leaf
DrugBank: Azadirachta indica leaf (DB14352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks
Trial: NCT03166163
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
Trial: NCT02150499
Drug: levalbuterol tartrate HFA inhalation aerosol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02768220
Drug: empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels
Trial: NCT02768220
Drug: linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels
Trial: NCT03131908
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.